ENGNW Company Profile and Key Details

Average 10-day trading volume of 9.16 thousand shares is below the 3-month average of 12.04 thousand, indicating normal recent market interest.

enGene Holdings Inc. Warrants earnings surprise history is a mixed track record. The quarter that ended September 08, 2026, missed forecasts by 10.16%. The prior quarter beat by -7.76%. Over the last six quarters, Apple has recorded several small beats. These include 1.75% in June 12, 2025.

enGene Holdings Inc. Warrants last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.36. This means the shares are trading below this model’s fair value.

enGene Holdings Inc. Warrants (NASDAQ:ENGNW) closed at $0.20 USD, losing -$0.03 (-13.04%) from the previous close of $0.23. The stock is currently mid-range between its 52-week high and low $0.18 and $2.10. With a market capitalization of about $10.24 million, enGene Holdings Inc. Warrants is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.28). Key stats such as the average daily volume over the past year has been around 13.26 thousand shares, in line with its 52-week average. Headquartered in Montreal, QC, enGene Holdings Inc. Warrants operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ronald H. W. Cooper, the company employs approximately 82 people and listed since February 01, 2022. EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines.

Our AI price prediction model suggests that enGene Holdings Inc. Warrants stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows enGene Holdings Inc. Warrants trading at a premium to the broader market with a P/E of -6.66.

enGene Holdings Inc. Warrants trades at a P/E ratio of -6.66, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.56 suggesting the stock is closer to book value. The P/FCF stands at -1.2, also above market averages.